U.S. pharma big copyright scrapped two experimental weight loss tablets very last calendar year—a as soon as-each day tablet, lotiglipron, resulting from elevated liver enzymes and a twice-daily tablet, danuglipron, because of solid Unintended effects—but CEO Albert Bourla has explai